---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-009483"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:15:08.801191+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences reports FY2021 net loss $33.2M; Phase 3 ORCA-2 topline data expected Q2 2022

## Summary
- Cash, cash equivalents and restricted cash of $43.1M as of Dec 31, 2021.
- Total operating expenses for FY2021 were $33.1M; net loss $33.2M.
- Initiated Phase 3 ORCA-3 trial; ORCA-2 completed with topline results due Q2 2022.
- Entered $25M loan facility with Silicon Valley Bank in December 2021.
- FDA accepted IND for cytisinicline in e-cigarette/vaping cessation; Phase 2 ORCA-V1 expected Q2 2022.

## SEC filing metadata
- accession: 0001564590-22-009483
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000156459022009483/0001564590-22-009483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000156459022009483/achv-8k_20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-009483
- JSON: https://secwatch.observer/filing/0001564590-22-009483.json
- Plain text: https://secwatch.observer/filing/0001564590-22-009483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.